SALT LAKE CITY, Oct ...ContinueReading. Mavrox - Roxus ... Consistent, well-tolerated effects. Less pharmacokinetic variability and a systemic adverse event profile comparable to oral PDE-5 inhibitors ... Mavrox will be the exclusive U.S ...Disclaimer ... 21% ... .